Vivesto AB Market Cap ($8.94 Million)
Market Cap & Net Worth: Vivesto AB (VIVE)
Vivesto AB market cap. Vivesto AB (ST:VIVE) has a market capitalization of $8.94 Million (Skr83.04 Million) as of November 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #27227 globally and #590 in its home market, demonstrating a 3.59% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vivesto AB's stock price Skr7.50 by its total outstanding shares 11071369 (11.07 Million). Also see Vivesto AB cash flow conversion for how efficiently the company converts equity into cash flow.
Vivesto AB Market Cap History (2015–2026)
Vivesto AB market cap history from 2015 to 2026. Data shows change from $7.93 Million to $8.94 Million (-3.05% CAGR). Check VIVE live share price for real-time trading data and today's change.
Vivesto AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vivesto AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore VIVE shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.51x
Vivesto AB's market cap is 0.51 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.85 Million | $172.00K | -$160.24 Million | 39.83x | N/A |
| 2017 | $2.06 Million | $3.17 Million | -$118.01 Million | 0.65x | N/A |
| 2018 | $7.18 Million | $1.98 Million | -$171.02 Million | 3.63x | N/A |
| 2019 | $4.93 Million | $201.84 Million | -$10.53 Million | 0.02x | N/A |
| 2020 | $4.91 Million | $201.84 Million | -$10.53 Million | 0.02x | N/A |
| 2021 | $3.13 Million | $26.19 Million | -$138.94 Million | 0.12x | N/A |
| 2022 | $517.09K | $1.01 Million | -$367.03 Million | 0.51x | N/A |
Competitor Companies of VIVE by Market Capitalization
Companies near Vivesto AB in the global market cap rankings as of November 4, 2026. Also see Vivesto AB asset portfolio for a full breakdown of the balance sheet.
Key companies related to Vivesto AB by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #534 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.90 |
| #580 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Vivesto AB (2015–2026)
Market capitalization of Vivesto AB from 2015 to today. Between 2015 and today, Vivesto AB's market cap moved from $7.93 Million to $ 8.94 Million, with a yearly change of -3.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr8.94 Million | +5455.56% |
| 2025 | Skr160.85K | -53.45% |
| 2024 | Skr345.52K | -28.83% |
| 2023 | Skr485.52K | -6.11% |
| 2022 | Skr517.09K | -83.45% |
| 2021 | Skr3.13 Million | -36.33% |
| 2020 | Skr4.91 Million | -0.48% |
| 2019 | Skr4.93 Million | -31.31% |
| 2018 | Skr7.18 Million | +249.23% |
| 2017 | Skr2.06 Million | -69.99% |
| 2016 | Skr6.85 Million | -13.61% |
| 2015 | Skr7.93 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Vivesto AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.94 Million USD |
| MoneyControl | $8.94 Million USD |
| MarketWatch | $8.94 Million USD |
| marketcap.company | $8.94 Million USD |
| Reuters | $8.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantri… Read more